Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients

doi:10.1016/j.clinimag.2022.03.012

	Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients
	Sun, Xiaojun 1,2; Song, Zhengbo 3,4; Jiang, Hongyang 1; Ma, Yanqing 1; Chen, Ming 2,5
刊名	CLINICAL IMAGING
	2022-06-01
卷号	86
关键词	Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor-related & nbsp Lung cancer Image classification pneumonia (ICIP)
ISSN号	0899-7071
DOI	10.1016/j.clinimag.2022.03.012
通讯作者	Chen, Ming(chenming@zjcc.org.cn)
英文摘要	Background: Immune checkpoint inhibitor-related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.& nbsp;Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.& nbsp;Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.& nbsp;Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/ 0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).& nbsp;Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.
资助项目	National Natural Science Foundation of China[81802276]
WOS关键词	ADVERSE EVENTS ; RISK
WOS研究方向	Radiology, Nuclear Medicine & Medical Imaging
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000793222200002
资助机构	National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130773]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Ming
作者单位	1.Hangzhou Med Coll, Affiliated Peoples Hosp, Zhejiang Prov Peoples Hosp, Canc Ctr,Dept Radiol, Hangzhou, Zhejiang, Peoples R China 2.Soochow Univ, Affiliated Hosp 2, Suzhou 215000, Jiangsu, Peoples R China 3.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou 310022, Zhejiang, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Clin Trial, Hangzhou 310022, Zhejiang, Peoples R China 5.Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Dept Radiat Oncol, Guangzhou 510060, Peoples R China
推荐引用方式 GB/T 7714	Sun, Xiaojun,Song, Zhengbo,Jiang, Hongyang,et al. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients[J]. CLINICAL IMAGING,2022,86.
APA	Sun, Xiaojun,Song, Zhengbo,Jiang, Hongyang,Ma, Yanqing,&Chen, Ming.(2022).Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.CLINICAL IMAGING,86.
MLA	Sun, Xiaojun,et al."Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients".CLINICAL IMAGING 86(2022).